Dendritic cell vaccination in melanoma patients: From promising results to future perspectives

Steve Boudewijns, Martine Bloemendal, Winald R. Gerritsen, I. Jolanda M de Vries, Gerty Schreibelt

Research output: Contribution to journalArticle

Abstract

Dendritic cells (DCs) play an important role in the induction of antitumor immunity. Therefore, they are used as anti-cancer vaccines in clinical studies in various types of cancer. DC vaccines are generally well tolerated and able to induce antigen-specific T cell responses in melanoma patients. After DC vaccinations, functional tumor-specific T cells are more frequently detected in stage III melanoma patients, as compared to patients with advanced melanoma, indicating that the tumor load influences immunological responses. Furthermore, long-lasting clinical responses were rarely seen in metastatic melanoma patients after DC vaccination. Since more potent treatment options are available, e.g. immune checkpoint inhibitors and targeted therapy, DC vaccination as monotherapy may not be preferred in the treatment of advanced melanoma. However, encouraging results of DC vaccines combined with ipilimumab have been reported in advanced melanoma patients with an objective response rate of 38%. DC vaccines show promising clinical results in stage III patients, although clinical efficacy still needs to be proven in a phase 3 trial. The clinical and immunological results of DC vaccination in stage III melanoma patients might be further improved by using naturally circulating DCs (myeloid DCs and plasmacytoid DCs) and neoantigens to load DCs.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalHuman Vaccines and Immunotherapeutics
DOIs
StateAccepted/In press - Jul 24 2016
Externally publishedYes

Fingerprint

Dendritic Cells
Melanoma
Vaccination
Vaccines
Combined Vaccines
T-Lymphocytes
Cancer Vaccines
Myeloid Cells
Tumor Burden
Immunity
Neoplasms
Therapeutics
Antigens

Keywords

  • Dendritic cell vaccination
  • immune checkpoint inhibitors
  • immune response
  • melanoma
  • naturally circulating dendritic cells
  • neoantigens

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Dendritic cell vaccination in melanoma patients : From promising results to future perspectives. / Boudewijns, Steve; Bloemendal, Martine; Gerritsen, Winald R.; de Vries, I. Jolanda M; Schreibelt, Gerty.

In: Human Vaccines and Immunotherapeutics, 24.07.2016, p. 1-6.

Research output: Contribution to journalArticle

Boudewijns, Steve ; Bloemendal, Martine ; Gerritsen, Winald R. ; de Vries, I. Jolanda M ; Schreibelt, Gerty. / Dendritic cell vaccination in melanoma patients : From promising results to future perspectives. In: Human Vaccines and Immunotherapeutics. 2016 ; pp. 1-6.
@article{4f899de051c84d8983bd3b57642e1740,
title = "Dendritic cell vaccination in melanoma patients: From promising results to future perspectives",
abstract = "Dendritic cells (DCs) play an important role in the induction of antitumor immunity. Therefore, they are used as anti-cancer vaccines in clinical studies in various types of cancer. DC vaccines are generally well tolerated and able to induce antigen-specific T cell responses in melanoma patients. After DC vaccinations, functional tumor-specific T cells are more frequently detected in stage III melanoma patients, as compared to patients with advanced melanoma, indicating that the tumor load influences immunological responses. Furthermore, long-lasting clinical responses were rarely seen in metastatic melanoma patients after DC vaccination. Since more potent treatment options are available, e.g. immune checkpoint inhibitors and targeted therapy, DC vaccination as monotherapy may not be preferred in the treatment of advanced melanoma. However, encouraging results of DC vaccines combined with ipilimumab have been reported in advanced melanoma patients with an objective response rate of 38{\%}. DC vaccines show promising clinical results in stage III patients, although clinical efficacy still needs to be proven in a phase 3 trial. The clinical and immunological results of DC vaccination in stage III melanoma patients might be further improved by using naturally circulating DCs (myeloid DCs and plasmacytoid DCs) and neoantigens to load DCs.",
keywords = "Dendritic cell vaccination, immune checkpoint inhibitors, immune response, melanoma, naturally circulating dendritic cells, neoantigens",
author = "Steve Boudewijns and Martine Bloemendal and Gerritsen, {Winald R.} and {de Vries}, {I. Jolanda M} and Gerty Schreibelt",
year = "2016",
month = "7",
day = "24",
doi = "10.1080/21645515.2016.1197453",
language = "English (US)",
pages = "1--6",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",

}

TY - JOUR

T1 - Dendritic cell vaccination in melanoma patients

T2 - From promising results to future perspectives

AU - Boudewijns, Steve

AU - Bloemendal, Martine

AU - Gerritsen, Winald R.

AU - de Vries, I. Jolanda M

AU - Schreibelt, Gerty

PY - 2016/7/24

Y1 - 2016/7/24

N2 - Dendritic cells (DCs) play an important role in the induction of antitumor immunity. Therefore, they are used as anti-cancer vaccines in clinical studies in various types of cancer. DC vaccines are generally well tolerated and able to induce antigen-specific T cell responses in melanoma patients. After DC vaccinations, functional tumor-specific T cells are more frequently detected in stage III melanoma patients, as compared to patients with advanced melanoma, indicating that the tumor load influences immunological responses. Furthermore, long-lasting clinical responses were rarely seen in metastatic melanoma patients after DC vaccination. Since more potent treatment options are available, e.g. immune checkpoint inhibitors and targeted therapy, DC vaccination as monotherapy may not be preferred in the treatment of advanced melanoma. However, encouraging results of DC vaccines combined with ipilimumab have been reported in advanced melanoma patients with an objective response rate of 38%. DC vaccines show promising clinical results in stage III patients, although clinical efficacy still needs to be proven in a phase 3 trial. The clinical and immunological results of DC vaccination in stage III melanoma patients might be further improved by using naturally circulating DCs (myeloid DCs and plasmacytoid DCs) and neoantigens to load DCs.

AB - Dendritic cells (DCs) play an important role in the induction of antitumor immunity. Therefore, they are used as anti-cancer vaccines in clinical studies in various types of cancer. DC vaccines are generally well tolerated and able to induce antigen-specific T cell responses in melanoma patients. After DC vaccinations, functional tumor-specific T cells are more frequently detected in stage III melanoma patients, as compared to patients with advanced melanoma, indicating that the tumor load influences immunological responses. Furthermore, long-lasting clinical responses were rarely seen in metastatic melanoma patients after DC vaccination. Since more potent treatment options are available, e.g. immune checkpoint inhibitors and targeted therapy, DC vaccination as monotherapy may not be preferred in the treatment of advanced melanoma. However, encouraging results of DC vaccines combined with ipilimumab have been reported in advanced melanoma patients with an objective response rate of 38%. DC vaccines show promising clinical results in stage III patients, although clinical efficacy still needs to be proven in a phase 3 trial. The clinical and immunological results of DC vaccination in stage III melanoma patients might be further improved by using naturally circulating DCs (myeloid DCs and plasmacytoid DCs) and neoantigens to load DCs.

KW - Dendritic cell vaccination

KW - immune checkpoint inhibitors

KW - immune response

KW - melanoma

KW - naturally circulating dendritic cells

KW - neoantigens

UR - http://www.scopus.com/inward/record.url?scp=84980016720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980016720&partnerID=8YFLogxK

U2 - 10.1080/21645515.2016.1197453

DO - 10.1080/21645515.2016.1197453

M3 - Article

C2 - 27322496

AN - SCOPUS:84980016720

SP - 1

EP - 6

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

ER -